Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 14 ... dosimeters, the radiation doses received by radiation team members performing Y-90-ibritumomab tiuxetan administration. The occupational doses associated with two injection methods for patient ...
2009 JUN 8 ... Blood report.
"The approved anti-CD20 radioimmunoconjugates (Y-90-ibritumomab tiuxetan or I-131-tositumomab) have had encouraging results, with trials now seeking to ...
2009 MAR 2 ... "There is no data about the efficacy and safety of radioimmunotherapy with Y-90-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma pretreated with ...
2009 NOV 2 ... with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin,' is newly published data in European Journal of Nuclear Medicine and ...
2009 MAR 16 ... whole body scans and SPECT/CT images, organ shapes and time-activity curves of 111In ibritumomab tiuxetan were measured in dosimetrically important organs in seven patients undergoing a high ...
2009 FEB 23 ... A total of 33 clinical patients received I-131-tositumomab (n = 23) or Y-90-ibritumomab tiuxetan (n = 10) and underwent F-18-FDG PET/CT scans before radioimmunotherapy and at 12 wk ...
2009 MAR 23 ... their study in Molecular Imaging and Biology (Radioisotopic Localization of (90)Yttrium-Ibritumomab Tiuxetan in Patients with CD20+Non-Hodgkin's Lymphoma. Molecular Imaging and Biology, ...
2009 JUN 15 ... Biotherapy and Radiopharmaceuticals (The Role of Dosimetry in the High Activity Y-90-Ibritumomab Tiuxetan Regimens: Two Cases of Abnormal Biodistribution. Cancer Biotherapy and ...
2009 MAR 30 ... acquired 100% control of RIT Oncology, LLC™, to commercialize ZEVALIN® ([90Y]-ibritumomab tiuxetan) in the United States. In connection with the closing, Spectrum Pharmaceuticals will pay ...
2009 MAR 9 ... for all manufacturing, sales, marketing, and commercialization activities for ZEVALIN® (ibritumomab tiuxetan).
ZEVALIN is currently approved for the treatment of patients with ...
2009 JUL 27 ... a study "To evaluate the efficacy and safety of treatment with Yttrium-90 (Y-90) ibritumomab tiuxetan following completion of short-course rituximab/chemotherapy in patients with previously ...
2009 JUN 30 ... St., New York, NY 10013, USA.
Keywords: Japan, Nagoya, Life Sciences, Ibritumomab Tiuxetan, Pharmaceuticals, Drugs, Therapy, Treatment, Biotechnology, Monoclonal Antibodies, ...
2009 JUN 15 ... this hybrid method to data from a clinical trial of high-dose myeloablative yttrium-90 ibritumomab tiuxetan therapy. Image data acquired from 18 patients were comprised of planar scans at five ...
